Malaysian Genomics partners De Cell to bring cell-gene therapy programme to market


Malaysian Genomics Resource Centre Bhd executive chairman Azri Azerai

KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd's (MGRC) wholly-owned subsidiary MGRC Healthcare Sdn Bhd is collaborating with De Cell Bhd for the commercialisation of the former's cell-gene therapy programme.

In a statement, the genomics and biopharmaceutical specialist said it will provide technical and production support to optimise the operational efficiency and market deployment of the EXOGENETIX programme.

De Cell will take on the role of exclusive marketing partner, overseeing all promotional and trademark activities to amplify the programme's market presence and success.

"This collaboration underscores MGRC’s commitment to spearheading innovation and transforming healthcare outcomes through advanced biotechnologies.

"By combining MGRC Healthcare's production capabilities with De Cell's marketing acumen, this partnership is poised to significantly advance the reach and effectiveness of the EXOGENETIX programme," said Malaysian Genomics executive chairman Azri Azerai.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Solidifying liquidity or cash buffer?
Sarawak gas deal under scrutiny
Scents with meaning
Ringgit slips against US$ on cautious sentiment
1Q GDP growth in line with advance estimates, higher than previous corresponding quarter- MOF
Samaiden unit inks RM108.6mil EPCC contract for LSSPV project
ACE Market-bound Oasis Home's IPO oversubscribed 1.55 times
Acme to dispose of Penang land for RM22mil
Bursa Malaysia in consolidation mode, CI ends marginally lower
Hong Kong economy expands 3.1% in first quarter

Others Also Read